Loading stock data…
INKT
$11.61-0.59 (-4.84%)
After Hours$11.61+0.00 (+0.00%)· Last close May 1
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MiNK Therapeutics, Inc. in the Healthcare sector is trading at $11.61. The stock is currently near its 52-week low of $6.34, remaining 10.1% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why INKT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.61
Potential Upside
5%
Whystock Fair Value$12.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$39.00+235.9%
Range$35.00 – $43.00
Fundamentals
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and othe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$56.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
87.82%
Volume
Today's trading volume
19,742
Recent News
MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ...
MiNK Therapeutics Inc (INKT) showcases robust financial growth and strategic clinical advancements, despite ongoing challenges.
MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q4 2025 earnings call
MiNK Therapeutics Q4 Earnings Call Highlights
MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform during its fourth quarter and year-end 2025 financial results conference call, highlighting updated clinical observations in solid tumors, plans to initiate randomized testing in s
Wall Street Stabilizes After Oil-Driven Volatility as US Equity Futures Waver Pre-Bell
US equity futures were cautiously lower ahead of Tuesday's opening bell as investor sentiment steadi
Agenus (AGEN) Q2 2025 Earnings Call Transcript
My name is Stefanie Nacar, and I'm the Chief Communications Officer here at Agenus. Welcome to our webcast where we'll be discussing topics related to patient care, their experiences, their needs and the work that's required to bring new options to those impacted by cancer, specifically colorectal cancer.